Italia markets close in 1 hour 46 minutes

Solid Biosciences Inc (B6C.MU)

Munich - Munich Prezzo differito. Valuta in EUR.
Aggiungi a watchlist
1,71860,0000 (0,00%)
In data: 02:31PM CEST. Mercato aperto.
Schermo intero
Chiusura precedente1,7186
Aperto1,7196
Denaro0,0000 x N/D
Domanda0,0000 x N/D
Min-Max giorno1,7186 - 1,7196
Intervallo di 52 settimane1,7186 - 25,7790
Volume300
Media Volume0
CapitalizzazioneN/D
Beta (mensile su 5 anni)N/D
Rapporto PE (ttm)N/D
EPS (ttm)N/D
Prossima data utili12 ago 2024 - 16 ago 2024
Rendimento e dividendo (futuro)N/D (N/D)
Data ex dividendoN/D
Stima target 1AN/D
  • GlobeNewswire

    Solid Biosciences Appoints Gabriel Brooks, M.D., as Chief Medical Officer

    - Dr. Brooks is a veteran drug development leader whose experience includes roles at Pfizer, 4D Molecular Therapeutics, and Gilead Life Sciences, which directly supports Solid’s focus on both neuromuscular and cardiac diseases - CHARLESTOWN, Mass., Oct. 02, 2023 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision genetic medicines for both neuromuscular and cardiac diseases, today announced the appointment of Gabriel Brooks, M.D., as Chief Medi

  • GlobeNewswire

    Solid Biosciences to Participate at Upcoming Investor Conferences

    CHARLESTOWN, Mass., Sept. 20, 2023 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing genetic medicines for neuromuscular and cardiac diseases, today announced that Bo Cumbo, President and Chief Executive Officer, will participate in the following three upcoming investor conferences: Jefferies Cell & Genetic Medicines Summit - New York, NYPresenting on Wednesday, September 27, 2023, at 10:00 AM ET.Cantor Global Healthcare Conference - New York, NYPresen

  • GlobeNewswire

    Solid Biosciences to Participate in Citi’s 18th Annual BioPharma Conference

    CHARLESTOWN, Mass., Aug. 31, 2023 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing genetic medicines for neuromuscular and cardiac diseases, today announced that Bo Cumbo, President and Chief Executive Officer, will present at the Citi 18th Annual BioPharma Conference on Thursday, September 7, 2023, at 9:40 AM ET. A live webcast of the presentation will be available on the Events page of the Investors section of the Company website or by clicking here